About Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals Inc (CRNX) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's proprietary platform utilizes a combination of computational modeling, structural biology, and medicinal chemistry to design and develop small molecule drugs that target specific hormone receptors. Its lead product candidate, CRN00808, is a selective nonpeptide somatostatin receptor agonist for the treatment of acromegaly and neuroendocrine tumors. The company is also developing other product candidates, including an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease and an oral nonpeptide ACTH agonist for the treatment of congenital adrenal hyperplasia (CAH).

Crinetics Pharmaceuticals Inc's stock price history has shown significant fluctuations over the years. However, it has shown a positive trend in recent months, with the stock price steadily increasing. As of the latest quote, the stock is trading at $30.50 per share. The market cap of Crinetics Pharmaceuticals Inc is approximately $1.03 billion. The PEG ratio of the stock is not readily available. However, it is important to note that the PEG ratio is a valuation metric that takes into account both the price-to-earnings (P/E) ratio and the expected earnings growth rate of a company. It is used to assess whether a stock is overvalued or undervalued relative to its growth prospects.